OSMR beta: cDNA Clones
Oncostatin M (OSM) is a cytokine originally isolated from medium conditioned by PMA-treated U-937 human histiocytic leukemia cells based on its ability to inhibit growth of A375 melanoma cells. The human OSM cDNA encodes a 252 amino acid pre-pro-OSM polypeptide with a 25 residue hydrophobic signal peptide and a hydrophilic C-terminal domain that are proteolytically processed to generate the 196 residue mature form of OSM. Although both mature and pro-OSM are equally active in radio-receptor assays, the mature OSM is 5- to 60-fold more active in growth inhibition assays.
Thus, proteolytic processing of the pro-OSM peptide may be important in regulating the in vivo activities of OSM. OSM initiates its biological activities by binding to specific cell surface receptors. The gp130, a signal-transducing component (beta subunit) of the IL-6, LIF, and CNTF receptor complexes, was identified as a low-affinity OSM receptor that does not transduce OSM signals. The low affinity LIF receptor (LIFR, a gp130-related protein) has now been identified to be a component of a high-affinity OSM receptor that will transduce OSM signals. Since OSM is also active on cells that do not express LIFR, a specific OSM receptor that does not involve LIFR must also exist.
Besides its growth inhibitory activities on human A375 melanoma and mouse M1 myeloid leukemic cells, as well as on other solid tumor cells, OSM also has growth stimulatory activities on normal fibroblasts, AIDS-Kaposis sarcoma cells, and a human erythroleukemia cell line, TF-1. Other OSM-mediated activities reported to date include: stimulation of plasminogen activator activity in cultured bovine aortic endothelial cells, regulation of IL-6 expression in human endothelial cells, and stimulation of LDL uptake and up-regulation of cell surface LDL receptors in HepG2 cells.
Human Oncostatin M (OSM) signals through two types of human OSM receptor complexes: the type I complex comprising the leukemia inhibitory factor receptor beta (LIFR beta) and gp130 and the type II complex made up of OSM receptor beta (OSMR beta) and gp130. In contrast, mouse OSM signals only through the mouse OSMR beta and gp130 complex. Human and mouse OSMR beta are 55% identical at the amino acid sequence level.
Products:
1 result for "OSMR beta cDNA Clones" in Products
1 result for "OSMR beta cDNA Clones" in Products
OSMR beta: cDNA Clones
Oncostatin M (OSM) is a cytokine originally isolated from medium conditioned by PMA-treated U-937 human histiocytic leukemia cells based on its ability to inhibit growth of A375 melanoma cells. The human OSM cDNA encodes a 252 amino acid pre-pro-OSM polypeptide with a 25 residue hydrophobic signal peptide and a hydrophilic C-terminal domain that are proteolytically processed to generate the 196 residue mature form of OSM. Although both mature and pro-OSM are equally active in radio-receptor assays, the mature OSM is 5- to 60-fold more active in growth inhibition assays.
Thus, proteolytic processing of the pro-OSM peptide may be important in regulating the in vivo activities of OSM. OSM initiates its biological activities by binding to specific cell surface receptors. The gp130, a signal-transducing component (beta subunit) of the IL-6, LIF, and CNTF receptor complexes, was identified as a low-affinity OSM receptor that does not transduce OSM signals. The low affinity LIF receptor (LIFR, a gp130-related protein) has now been identified to be a component of a high-affinity OSM receptor that will transduce OSM signals. Since OSM is also active on cells that do not express LIFR, a specific OSM receptor that does not involve LIFR must also exist.
Besides its growth inhibitory activities on human A375 melanoma and mouse M1 myeloid leukemic cells, as well as on other solid tumor cells, OSM also has growth stimulatory activities on normal fibroblasts, AIDS-Kaposis sarcoma cells, and a human erythroleukemia cell line, TF-1. Other OSM-mediated activities reported to date include: stimulation of plasminogen activator activity in cultured bovine aortic endothelial cells, regulation of IL-6 expression in human endothelial cells, and stimulation of LDL uptake and up-regulation of cell surface LDL receptors in HepG2 cells.
Human Oncostatin M (OSM) signals through two types of human OSM receptor complexes: the type I complex comprising the leukemia inhibitory factor receptor beta (LIFR beta) and gp130 and the type II complex made up of OSM receptor beta (OSMR beta) and gp130. In contrast, mouse OSM signals only through the mouse OSMR beta and gp130 complex. Human and mouse OSMR beta are 55% identical at the amino acid sequence level.
Products:
